NewsMV
In focus: AIM ImmunoTech (NYSE American: AIM) and a July 31, 2026, Proposal Agreement with contract manufacturer Sterling Pharma Solutions that commits approximately $1.5 million over 12 months to produce fresh batches of the polynucleotide drug substances PolyI and Poly C12U at Sterling's Dudley, UK facility.
The manufactured output feeds the polymer precursor chain for Ampligen, AIM's experimental drug candidate.
The next confirmable milestone is whether that batch production, and the transfer of associated test methods, come in on the 12-month schedule the agreement describes.
The manufacturing commitment The Proposal Agreement builds on a relationship formalized in 2022, when AIM ImmunoTech and Sterling Pharma Solutions signed both a Master Service Agreement and a Quality Agreement.
Keep reading